Study finds influenza A/H1N1 MF59 adjuvanted vaccine (Focetria®) in pregnant women does not increase risk of adverse perinatal outcomes

Source: BMJ Area: News According to research published early online in the British Medical Journal (BMJ), vaccination during pregnancy with the MF59 adjuvanted A/H1N1 influenza vaccine does not increase (and may even lower) the risk of adverse perinatal events.   The authors note that data on the use of MF59 adjuvanted vaccines during pregnancy are scarce. Although limited evidence provides some reassurance, the uptake of H1N1 specific influenza vaccine in pregnant women has been poor in several countries as a result of uncertainty (among both women and physicians) about safety of the vaccine in pregnancy.    Following the 2009 influenza pandemic, the Argentinean Ministry of Health launched a national immunisation programme that included pregnant women, among other risk groups. Although other influenza A/H1N1 vaccines were also available in the private market, the programme used only a single dose of the inactivated virus MF59 adjuvanted vaccine (Focetria®). In the context of ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news